From fixed antibody-drug conjugates to programmable therapeutics.

Antibody-drug conjugates have long been designed as fixed therapeutic entities. In Nature, Simó et al. introduce in vivo molecular assembly as an alternative strategy, prompting a broader question: could future cancer therapeutics be engineered by programming molecular interactions within patients rather than constructing increasingly complex drugs beforehand?